13 Jan 2020 --- Nestlé Health Science (NHSc) and Codexis – a biotherapeutics developer – have signed an agreement to advance the development of CDX-7108, the lead candidate for the potential treatment of a gastrointestinal (GI) disorder called phenylketonuria. In 2017, the companies signed a Strategic Collaboration Agreement (SCA) for preclinical development and early clinical studies to co-discover new enzyme therapy candidates for NHSc’s nutritional therapies portfolio. The agreement led to the discovery of CDX-7108, which is an orally administered enzyme. The research will be extended through the end of 2021 to support the discovery of therapeutic candidates for additional disorders, NHSc notes.
